---
title: "Norgestrel - Postmenopausal osteoporosis"
sidebar: mydoc_sidebar
permalink: db09389-mesh-d015663-1.html
toc: false 
---


Path ID: `DB09389_MESH_D015663_1`
{% include image.html url="images/db09389-mesh-d015663-1.png" file="db09389-mesh-d015663-1.png" alt="db09389-mesh-d015663-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D009644 | Norgestrel | Drug |
| MESH:D015663 | Postmenopausal osteoporosis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Norgestrel | TREATS | Postmenopausal Osteoporosis |
|---------|-----------|---------|

Comment: Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer (levonorgestrel) is biologically active. Norgestrel is prescribed in combination with estradiol as a hormone therapy during menopause to prevent osteoporosis and in this case estradiol is the acive drug that prevents oseoporosis, while norgestrel is added for the protection of the endometrium

Reference: [https://go.drugbank.com/drugs/DB09389#mechanism-of-action](https://go.drugbank.com/drugs/DB09389#mechanism-of-action){:target="_blank"}